辅助因子对NAFLD/NASH和MAFLD的影响。说明器官功能障碍的病理力学的范例。

IF 3.9
Metabolism and target organ damage Pub Date : 2022-01-01 Epub Date: 2022-08-22 DOI:10.20517/mtod.2022.14
Amedeo Lonardo, Ashwani K Singal, Natalia Osna, Kusum K Kharbanda
{"title":"辅助因子对NAFLD/NASH和MAFLD的影响。说明器官功能障碍的病理力学的范例。","authors":"Amedeo Lonardo,&nbsp;Ashwani K Singal,&nbsp;Natalia Osna,&nbsp;Kusum K Kharbanda","doi":"10.20517/mtod.2022.14","DOIUrl":null,"url":null,"abstract":"<p><p>Primary nonalcoholic fatty liver disease (NAFLD) is bi-directionally associated with the metabolic syndrome and its constitutive features (\"factors\": impaired glucose disposal, visceral obesity, arterial hypertension, and dyslipidemia). Secondary NAFLD occurs due to endocrinologic disturbances or other cofactors. This nosography tends to be outdated by the novel definition of metabolic associated fatty liver disease (MAFLD). Irrespective of nomenclature, this condition exhibits a remarkable pathogenic heterogeneity with unpredictable clinical outcomes which are heavily influenced by liver histology changes. Genetics and epigenetics, lifestyle habits [including diet and physical (in)activity] and immunity/infection appear to be major cofactors that modulate NAFLD/MAFLD outcomes, including organ dysfunction owing to liver cirrhosis and hepatocellular carcinoma, type 2 diabetes, chronic kidney disease, heart failure, and sarcopenia. The identification of cofactors for organ dysfunction that may help understand disease heterogeneity and reliably support inherently personalized medicine approaches is a research priority, thus paving the way for innovative treatment strategies.</p>","PeriodicalId":91001,"journal":{"name":"Metabolism and target organ damage","volume":"2 3","pages":""},"PeriodicalIF":3.9000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9453927/pdf/","citationCount":"14","resultStr":"{\"title\":\"Effect of cofactors on NAFLD/NASH and MAFLD. A paradigm illustrating the pathomechanics of organ dysfunction.\",\"authors\":\"Amedeo Lonardo,&nbsp;Ashwani K Singal,&nbsp;Natalia Osna,&nbsp;Kusum K Kharbanda\",\"doi\":\"10.20517/mtod.2022.14\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Primary nonalcoholic fatty liver disease (NAFLD) is bi-directionally associated with the metabolic syndrome and its constitutive features (\\\"factors\\\": impaired glucose disposal, visceral obesity, arterial hypertension, and dyslipidemia). Secondary NAFLD occurs due to endocrinologic disturbances or other cofactors. This nosography tends to be outdated by the novel definition of metabolic associated fatty liver disease (MAFLD). Irrespective of nomenclature, this condition exhibits a remarkable pathogenic heterogeneity with unpredictable clinical outcomes which are heavily influenced by liver histology changes. Genetics and epigenetics, lifestyle habits [including diet and physical (in)activity] and immunity/infection appear to be major cofactors that modulate NAFLD/MAFLD outcomes, including organ dysfunction owing to liver cirrhosis and hepatocellular carcinoma, type 2 diabetes, chronic kidney disease, heart failure, and sarcopenia. The identification of cofactors for organ dysfunction that may help understand disease heterogeneity and reliably support inherently personalized medicine approaches is a research priority, thus paving the way for innovative treatment strategies.</p>\",\"PeriodicalId\":91001,\"journal\":{\"name\":\"Metabolism and target organ damage\",\"volume\":\"2 3\",\"pages\":\"\"},\"PeriodicalIF\":3.9000,\"publicationDate\":\"2022-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9453927/pdf/\",\"citationCount\":\"14\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Metabolism and target organ damage\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.20517/mtod.2022.14\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2022/8/22 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Metabolism and target organ damage","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.20517/mtod.2022.14","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/8/22 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 14

摘要

原发性非酒精性脂肪性肝病(NAFLD)与代谢综合征及其构成特征(“因素”:葡萄糖处理受损、内脏肥胖、动脉高血压和血脂异常)双向相关。继发性NAFLD的发生是由于内分泌紊乱或其他辅助因素。由于代谢性脂肪性肝病(MAFLD)的新定义,这种疾病诊断往往已经过时。不考虑命名法,这种情况表现出显著的致病异质性和不可预测的临床结果,严重影响肝脏组织学变化。遗传和表观遗传学、生活习惯(包括饮食和身体活动)和免疫/感染似乎是调节NAFLD/MAFLD结局的主要辅助因素,包括肝硬化和肝细胞癌、2型糖尿病、慢性肾病、心力衰竭和肌肉减少症引起的器官功能障碍。识别器官功能障碍的辅助因素可能有助于了解疾病异质性并可靠地支持固有的个性化医疗方法,这是研究的重点,从而为创新治疗策略铺平道路。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Effect of cofactors on NAFLD/NASH and MAFLD. A paradigm illustrating the pathomechanics of organ dysfunction.

Effect of cofactors on NAFLD/NASH and MAFLD. A paradigm illustrating the pathomechanics of organ dysfunction.

Primary nonalcoholic fatty liver disease (NAFLD) is bi-directionally associated with the metabolic syndrome and its constitutive features ("factors": impaired glucose disposal, visceral obesity, arterial hypertension, and dyslipidemia). Secondary NAFLD occurs due to endocrinologic disturbances or other cofactors. This nosography tends to be outdated by the novel definition of metabolic associated fatty liver disease (MAFLD). Irrespective of nomenclature, this condition exhibits a remarkable pathogenic heterogeneity with unpredictable clinical outcomes which are heavily influenced by liver histology changes. Genetics and epigenetics, lifestyle habits [including diet and physical (in)activity] and immunity/infection appear to be major cofactors that modulate NAFLD/MAFLD outcomes, including organ dysfunction owing to liver cirrhosis and hepatocellular carcinoma, type 2 diabetes, chronic kidney disease, heart failure, and sarcopenia. The identification of cofactors for organ dysfunction that may help understand disease heterogeneity and reliably support inherently personalized medicine approaches is a research priority, thus paving the way for innovative treatment strategies.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
3.00
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信